Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: experience from University Hospital in Chile

Simple item page
dc.coverageDOI: 10.1111/hel.13052
dc.creatorvon Muhlenbrock, Christian
dc.creatorCordova, Andrea
dc.creatorNuñez, Paulina
dc.creatorPacheco, Nicole
dc.creatorHerrera, Karin
dc.creatorQuera, Rodrigo
dc.date2024
dc.date.accessioned2025-11-18T19:49:36Z
dc.date.available2025-11-18T19:49:36Z
dc.description<p>Introduction: In Chile, more than 70% of adults are infected by Helicobacter pylori. Clarithromycin should not be used in any regimen if there is &gt;15% resistance to this antibiotic, being greater than 26% in our population. In this scenario, the effectiveness of triple therapy (proton pump inhibitor [PPI], clarithromycin, amoxicillin) was only 63.8%. Aim: To evaluate the eradication rate and safety of dual therapy (esomeprazole and amoxicillin) in high doses, through a prospective, observational, and descriptive study. Methods: Patients with a positive urease test obtained in an upper digestive endoscopy were included. Any other previous H. pylori eradication regimen were excluded. All patients were treated with esomeprazole 40 mg three times a day and amoxicillin 750 mg four times a day for 14 days. The eradication rate of the dual therapy was evaluated with the H. pylori stool antigen test (the Pylori-Strip® test used) 6 weeks after completing the eradication treatment and with at least 14 days without PPI, being a negative result, confirmation of the effectiveness of this regimen. Results: Of 122 patients, 106 had a negative H. pylori antigen in stool; The intention-to-treat and per protocol analysis, the eradication rates were 91.8% [95% CI: 87%–97%] and 94% [95% CI: 90%–98%], respectively. Four patients discontinued treatment due to adverse effects. Smoking and adherence to treatment were associated with eradication rate. Conclusions: In this cohort of patients with H. pylori infection, high-dose dual therapy has a high eradication rate and good adherence, raising the possibility that it could be used as first-line therapy in our country. Studies with a larger number of patients should confirm these results.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/6368549c-62df-4182-a2e8-43e2ff164998
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/56179
dc.languageeng
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.29 (2024) date: 2024-02-08 nr.1 p.1-8
dc.subjectAdult
dc.subjectAmoxicillin
dc.subjectAnti-Bacterial Agents
dc.subjectChile
dc.subjectClarithromycin/therapeutic use
dc.subjectDrug Therapy, Combination/adverse effects
dc.subjectEsomeprazole/therapeutic use
dc.subjectHelicobacter Infections/drug therapy
dc.subjectHelicobacter pylori
dc.subjectHospitals
dc.subjectHumans
dc.subjectProspective Studies
dc.subjectProton Pump Inhibitors
dc.subjectTreatment Outcome
dc.subjectSDG 3 - Good Health and Well-being
dc.titleEradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: experience from University Hospital in Chileeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE